Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.
Read original at benzingaStocks · News reference
8-K filing — Pelthos Therapeutics Inc. (PTHS)
Filed: 2026-08-13 AccNo: 0001919246-26-000110 Size: 153 KB Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 13, 2026, 11:00 AM
- Checked
- Aug 13, 2026, 11:00 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Pelthos Therapeutics (AMEX:PTHS) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and
Read original at benzinga8-K filing — Pelthos Therapeutics Inc. (PTHS)
Filed: 2026-08-13 AccNo: 0001919246-26-000112 Size: 4 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarPelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses of $(5.38) per share
Read original at benzinga